Superior visual quality outcomes with compound tropicamide eye drops in treating juvenile pseudomyopia

To evaluate the impact of Compound Tropicamide (Trop) Eye Drops on the visual quality in juvenile pseudomyopia patients. Data from 111 juvenile pseudomyopia patients treated between September 2019 and September 2022 were reviewed in this retrospective study, including 50 cases treated with Atropine Sulfate Ophthalmic Gel (control group) and 61 with Compound Trop Eye Drops (research group). Clinical efficacy, amplitude of accommodation (AA), uncorrected visual acuity (UCVA), intraocular pressure (IOP), axial length (AL), symptom improvement, complications, and quality of life were compared. Risk factors for visual quality improvement were analyzed using Logistic regression. The research group demonstrated significantly higher treatment efficacy compared to the control group (P>0.05). Post-treatment, AA, IOP, and AL decreased notably in the research group compared to baseline and the control group (all P<0.05). UCVA and quality of life scores improved significantly in the research group (both P<0.05). Recovery indicators, including resolution of dizziness, alleviation of ocular soreness, and vision recovery, were significantly shorter in the research group (all P<0.05). Both groups had similar complication rates, including dry mouth, facial blushing, conjunctival congestion, and transient tachycardia (P>0.05). The research group reported superior post-treatment quality of life across all domains (all P<0.05). Logistic regression showed that gender, age, disease duration, family history of myopia, education level, AA, UCVA, and treatment method were not significant risk factors for visual quality improvement (all P>0.05). Compound Trop Eye Drops effectively enhances visual function and quality of life in juvenile pseudomyopia patients, with a safety profile comparable to low-dose atropine, offering potential clinical value.